Best Oncology Companies in Baltimore, United States
The 31 best Oncology companies in Baltimore, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Delfi Diagnostics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Baltimore
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 11 mo ago | Series B | 197 | Victor Velculescu Founder and Board of Directors | 52 patents Liquid biopsy cancer detection using cfDNA fragmentation and methylation profiling | — |
| 2 | Personal Genome Provider of advanced technology solutions for cancer genome analysis | $252M | 69 mo ago | Acquired | 109 | — | 143 patents Genomic sequencing platforms and AI-driven cancer diagnostics for personalized medicine | — |
| 3 | Haystack Oncology Provider of personalized cancer diagnostic tests | $67M | 48 mo ago | Acquired | 45 | — | — | — |
| 4 | Gliknik Discovering and developing innovative biologics for immune disorders and cancers 22Funding top 21%Moat top 21%Product top 25%Patents top 31% All 9 signals ▾Fundingtop 21% Moattop 21% Producttop 25% Patentstop 31% Innovationtop 33% Globalbottom 36% Newsbottom 22% Marketbottom 20% Techbottom 16% Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $60M | 14 mo ago | Series C | 6 | — | 246 patents Engineered multimeric Fc fusion proteins enhancing complement binding for therapeutic antibodies | — |
| 5 | AsclepiX Therapeutics Developing anti-angiogenic therapeutics | $58M | 39 mo ago | Series A | 8 | — | — | — |
| 6 | Dracen Developer of thaerapeutics for the treatment of cancers | $57M | 56 mo ago | Series A | 8 | Thomas Estok CEO & President | — | — |
| 7 | Rapafusyn Developer of therapeutics for treatment of multiple diseses | $28M | 14 mo ago | Series A | 3 | Sean Hu CEO | — | — |
| 8 | Vaccinogen Exploring video game history, developers, and software providers | $17M | 132 mo ago | Public | 24 24 → 12 (-50%) | — | 6 patents Personalized autologous tumor vaccine development targeting adenocarcinoma antigens. | — |
| 9 | VerImmune Developer of vaccines for the treatment of cancer | $10M | 18 mo ago | Seed | 7 | John Troyer Founder & COO | 36 patents Virus-like particle platforms for cancer immunotherapy and immune response redirection | — |
| 10 | Flavocure Biotech Developing next-generation oncology solutions inspired by nature for cancer treatment | $8M | 21 mo ago | Series A | — | Henry Lowe Co-Founder | — | — |
| 11 | OncoSTING Developer of immunotherapy for bladder cancer | $5M | 11 mo ago | Funding Raised | 3 | William Bill Bishai Co-Founder | — | — |
| 12 | Papgene Diagnostics company focused on commercializing molecular tests for early detection of cancer | $3M | 129 mo ago | Deadpooled | — | Luis Diaz Founder | — | — |
| 13 | Previse Provider of diagnostic tests for the detection of cancer | $3M | 37 mo ago | Acquired | 10 | Dan Lunz Co-Founder & CEO | — | — |
| 14 | Irazu Oncology Developer of vaccines for colorectal cancer patients | $3M | 34 mo ago | Seed | 2 | Marco Chacon Founder | 5 patents Engineered Salmonella typhi live vectors delivering tumor antigens for cancer immunotherapy | — |
| 15 | WindMIL Developer of therapeutics for cancer | $2M | 69 mo ago | Seed | 2 | Don Hayden Chairman & CEO | — | — |
| 16 | Cage Pharma Developer of drugs targeting the tumor metabolism | $2M | 30 mo ago | Series A | — | Jeff Geschwind Founder | — | — |
| 17 | CCC DirectHit Pharmacodiagnostic test for breast cancer | $745K | 189 mo ago | Deadpooled | — | John Hughes CEO & President | — | — |
| 18 | Avidea Technologies Developer of immunotherapies through polymer-drug conjugate technologies | $696K | 56 mo ago | Acquired | 15 | Richard Laga Co-Founder | 4 patents Firearm discharge detection and signaling systems for safety and incident monitoring | — |
| 19 | Capsulomics Developer of methylation based diagnostic tests for esophageal cancer risk | $200K | 59 mo ago | Seed | 13 | Daniel Lunz Co-Founder & CEO | 4 patents Predictive analytics for Barrett's esophagus progression using AI-driven clinical decision support | — |
| 20 | Adventris Developer of immuno-therapeutics for cancer treatment | $125K | 40 mo ago | Seed | 2 | William Collis Co-Founder | — | — |
Top 12 Oncology companies in Baltimore
#1
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
#2
Series C · Baltimore, Maryland · founded 2007 · 6 employees$60.3Mraised▾
Discovering and developing innovative biologics for immune disorders and cancers. The company focuses on modulating the immune system to create new treatment options for autoimmune diseases and cancers. They are advancing multiple drugs through clinical trials, including recombinant Fc fusion proteins designed to mimic or inhibit specific immune pathways. Their approach involves a team of talented scientists, board members, scientific advisors, and a network of global thought leaders. They aim to make a significant difference in the lives of individuals with immune disorders through innovative drug discovery and development. Their expertise lies in biologics, clinical trials, drug design, protein production, purification, and analysis, targeting autoimmune diseases and cancers.
- Aug 2025Series C$11M
- Nov 2024Series C$5.3M
- Jul 2023Series C$5.4M
- Jun 2021Series C$11.5M
#3
Series A · Baltimore, Maryland · founded 2015 · 3 employees$28Mraised▾
Developer of therapeutics for treatment of multiple diseses. It offers platform that screens libraries of hybrid macrocycles to discover lead compound rapafucin-FKBP complexes against novel and validated targets which include oncology, immunosuppression, ischemic reperfusion injury, and neurodegenerative diseases.
- Sep 2025Series A—
- Jun 2024Series A$28M
#4
Funding Raised · Baltimore, Maryland · founded 2018 · 3 employees$5Mraised▾
Developer of immunotherapy for bladder cancer. The lead candidate OS-101 is a STING agonist and BCG-based immunotherapy for bladder cancer that trigger proinflammatory innate immune responses against tumors.
- Dec 2025Grant (prize money)$2.2M
- Jun 2024Grant (prize money)$270.2K
- Jun 2022Grant (prize money)$256K
- Sep 2021Grant (prize money)$2.2M
#5
Seed · Baltimore, Maryland · founded 2019 · 7 employees$10.1Mraised▾
Developer of vaccines for the treatment of cancer. The company is developing Anti-tumor Immune Redirection (AIR) a therapy that redirects the pre-existing immune memory from childhood vaccines or infections to fight cancer. They have developed a papillomavirus nanoparticle conjugated with viral antigens to treat cancer.
- Apr 2025Grant (prize money)$470.4K
- Sep 2024Seed$4.5M
- Sep 2023Seed$3.1M
- Jul 2022Seed$2.5M
#6
Series A · Baltimore, Maryland · founded 2014$8.4Mraised▾
Developing next-generation oncology solutions inspired by nature for cancer treatment. The company focuses on transforming natural products into innovative cures for patients, particularly in oncology. They are discovering and advancing promising drug candidates through clinical research, targeting driver mutations implicated in cancer. Their lead drug candidate has received FDA Orphan Drug Designation for pancreatic cancer, and their research extends to other cancers like Glioblastoma, Acute Myeloid Leukemia, and Multiple Myeloma. The company collaborates with research institutions to develop new therapeutics for cancer treatment. They are exploring partnering opportunities with pharmaceutical and biotechnology companies to expand into various therapeutic areas. The company is dedicated to addressing unmet needs in cancer care through innovative, nature-inspired solutions.
- Feb 2025Series A$215K
- Jan 2023Series A$1.1M
- Sep 2019Series A$1.5M
- Nov 2018Series A$5.8M
#7
Series A · Baltimore, Maryland · founded 2011 · 8 employees$58Mraised▾
AsclepiX Therapeutics LLC represents the next generation of biologics and drug development technology. We use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular) and anti-lymphangiogenic peptides, and they use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano- and microparticles to deliver these biomimetic therapeutic peptides throughout the body. They are utilizing our platform technology for indications in ophthalmology, oncology, and for other angiogenesis- and lymphangiogenesis-dependent diseases. They are initially targeting Macular Edema, Neovascular Age-Related Macular Degeneration (wet AMD), and solid tumors with other applications to follow.
- Jul 2023Series A$10M
- Jun 2020Series A$35M
- Sep 2019Grant (prize money)$299.7K
- Jun 2019Series A$7.7M
#8
Acquired · Baltimore, Maryland · founded 2010 · 109 employees$252.4Mraised▾
Provider of advanced technology solutions for cancer genome analysis. PGDx has developed proprietary techniques that identify mutations found in a patient’s tumor through noninvasive testing of circulating tumor DNA. PGDx is CLIA certified for high-complexity molecular testing using the whole exome, targeted and plasma analysis approaches.
- Feb 2021Series C$103M
- May 2020Series B$2.8M
- Jun 2019Series B$5M
- Oct 2018Series B$42M
#9
Acquired · Baltimore, Maryland · founded 2021 · 45 employees$67Mraised▾
Provider of personalized cancer diagnostic tests. It offers circulating tumor DNA detection technology to optimize minimal residual disease (MRD) testing for recurrent or resistant diseases. It also has a tumor-informed liquid biopsy-based test that begins with tissue-based whole-exome sequencing to identify patient-specific tumor mutations.
- Oct 2022Series A$67M
#10
Series A · Baltimore, Maryland · founded 2017 · 8 employees$57Mraised▾
Developer of therapeutics for the treatment of cancers. It offers Sirpiglenastat (DRP-104) is a glutamine inhibitor that inhibits all known enzymes involved in glutamine metabolism and has anti-tumor activity across multiple tumor.
- Mar 2022Series A$2M
- Nov 2021Series A$8.6M
- Jan 2018Series A$40M
#11
Series A · Baltimore, Maryland · founded 2017$2.1Mraised▾
Developer of drugs targeting the tumor metabolism. It offers a lead compound CP-102 that target cancer by directly attacking tumor glycolysis enabling medical practitioners to achieve efficacy as an anti-cancer agent.
- May 2024Series A$137.5K
- Apr 2017Series A$2M
#12
Acquired · Baltimore, Maryland · founded 2018 · 10 employees$3Mraised▾
Provider of diagnostic tests for the detection of cancer. The company is developing precision medicine solutions for the prevention and earlier detection of cancer, starting with esophageal cancer. The company's lead product is "Esopredict" a molecular test that provides personalized guidance for Barrett’s esophagus surveillance and treatment decisions.
- Oct 2023Grant (prize money)$1.8M
- Mar 2023Seed$3M
- Dec 2019Seed$2.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Baltimore is moving
A read on the academic research around Oncology in Baltimore — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 98 papers.
- University of Maryland, Baltimore56
- University of Baltimore44
- University of Maryland, Baltimore County4
- Baltimore VA Medical Center1
- Tumor microenvironment14
- Cancer research9
- Cancer7
- Immune system6
- Metastasis4
- Cancer research1→18
- Immune system5→21
- Tumor microenvironment3→19
- Cancer2→6
- Tumor microenvironment2→4
- Immune system2→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.